Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.73
+0.45 (3.35%)
Jan 22, 2026, 3:03 PM EST - Market open
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 87.27B INR in the quarter ending December 31, 2025, with 4.40% growth. This brings the company's revenue in the last twelve months to 346.33B, up 11.06% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
346.33B INR
Revenue Growth
+11.06%
P/S Ratio
2.87
Revenue / Employee
12,452,806 INR
Employees
27,811
Market Cap
11.06B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -15.09B | -23.18% |
| Mar 31, 2007 | 65.10B | 40.83B | 168.24% |
| Mar 31, 2006 | 24.27B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.12B |
| Elanco Animal Health | 4.59B |
| United Therapeutics | 3.13B |
| Amneal Pharmaceuticals | 2.93B |
| Neurocrine Biosciences | 2.68B |
| Hims & Hers Health | 2.21B |
| Lantheus Holdings | 1.53B |
| Alkermes | 1.52B |
RDY News
- 22 hours ago - Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S. - Business Wire
- 7 weeks ago - Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies - Business Wire
- 3 months ago - Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds - Seeking Alpha
- 3 months ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 3 months ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 5 months ago - Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - GlobeNewsWire
- 6 months ago - Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript - Seeking Alpha